Invivyd, Inc. (IVVD)
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn moreKey Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
|
Mr. Marc William Elia
|
CEO & Chairperson of the Board | 85.5k | -- | 1976 |
|
Mr. William E. Duke Jr., M.B.A.
|
CFO and Principal Financial & Accounting Officer | 752.78k | -- | 1972 |
|
Ms. Jill Andersen J.D.
|
Chief Legal Officer & Corporate Secretary | 775.71k | -- | 1973 |
|
Mr. Timothy Lee
|
Chief Commercial Officer | 706.87k | -- | 1974 |
|
Dr. Robert D. Allen Ph.D.
|
Chief Scientific Officer | 828.18k | -- | 1970 |
|
Ms. Kristie Coneys Kuhl J.D.
|
Chief Communications Officer | -- | -- | -- |
|
Ms. Julie Green M.B.A.
|
Chief Human Resources Officer | 542.35k | -- | 1976 |
|
Ms. Rachael Gerlach Ph.D.
|
Senior Vice President of Regulatory Affairs | -- | -- | -- |
|
Ms. Katie Falzone CPA
|
Senior Vice President of Finance | -- | -- | -- |
|
Dr. Michael J. Mina M.D., Ph.D.
|
Chief Medical Officer & Chief Epidemiologist | -- | -- | 1984 |
Invivyd, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 122
Description
Invivyd, Inc., together with its subsidiaries, engages in the research, development, commercialization, and sale of antibody therapies for the prevention and treatment of viral infectious diseases in the United States. The company offers Pemivibart, a half-life extended investigational monoclonal antibody for the pre-exposure prophylaxis prevention of COVID-19 in adults and adolescents through injection under the PEMGARDA brand. It also develops VYD2311, a monoclonal antibody, which is in Phase III clinical trial for the prevention and treatment of SARS-CoV-2 virus; and VBY329, a monoclonal antibody, which is in pre-clinical trial stage for the prevention and treatment of respiratory syncytial virus and measles in neonates, infants, and children. It has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in New Haven, Connecticut.
Corporate Governance
Upcoming Events
November 5, 2026 at 9:00 PM UTC
Invivyd, Inc. Earnings Date
